INTRODUCTION
differentiate individuals prone to therapeutic failure or success. 1 Clinical pharmacogenomics is powerful tool that can define disease more precisely, associate drug response to genetic markers, and predict adverse effects. 4 About 50 years of pharmacogenetic (PGx) research has brought up the light of hope to build a successful drug therapy but for the incorporation of the successful concept of PGx there is still a need of concrete clinical recommendations on individualization of drug. 5 Newer linking hypothesis can be generated to support the notion of PGx, polymorphism and therapeutic efficacy in a convenient fashion.
Pharmacogenetics and polymorphism
The word 'pharmacogenetics' was originally proposed by Friedrich Vogel in 1959 to describe studies of the genetic basis of therapeutics and it encompass genetics, pharmacology and biochemistry. 4, 6 Similar word "pharmacogenomics" cover newer sciences of molecular biology, genomics and bioinformatics and their associated technologies. 4 In early times haemolytic anaemia was seen in individuals lacking glucose-6-phosphate. 7 The interest of Pharmacogenetics came into being in the 1950s with the realization of altered drug response as a consequence of gene based variation of enzyme activities in few compounds such as hemolysis caused by primaquine in glucose-6-phosphate dehydrogenase variants, peripheral neuropathy caused by isoniazid in poor acetylators, prolonged muscle relaxation caused by suxamethonium in cholinesterase deficient inheritants. 8 In 1980s defective hydroxylation of debrisoquine was known to be due to CYP2D6 polymorphism. 7 The inter-individual common variation in the DNA sequence due to different nucleotides at a common position within a gene results in variable form of genes. If the variability is greater than 1% of a population then it is called genetic polymorphism. 7, 9 Preferentially PGx describes the variability in pharmacokinetics, efficacy and toxicity of drugs based on genetic differences. 5 The majority of identified PGx polymorphisms are in the drugmetabolizing enzymes. PGx polymorphisms do significantly occur at the level of drug transporters and targets. The so called "genome-based drug discovery" is getting more popularity these days that focuses in the identification of transporters and target proteins. 9, 10, 11 The consequences of pharmacogenetic polymorphism in therapeutic efficacy are discussed in paragraphs ahead.
Pharmacogenetic polymorphism in drug-metabolizing enzymes
PGx polymorphism in drug-metabolizing enzymes is one of the major concerns for inter-individual variation in drug disposition. 6 Drug-metabolizing enzymes catalyze phase I and II reactions. The Phase I metabolism (oxidation, reduction or hydrolysis) of most drugs is mainly catalyzed by cytochrome P450 enzymes (CYPs) to detoxifiy or to activate inactive prodrug. 7 The phase I products, other reactive intermediates, or the parent compounds are mainly conjugated through the Phase II metabolic pathway catalyzed by enzymes such as UDPglucoronyltransferases (UGTs), N-acetyl transferases (NAT1 and NAT2), glutathione S-transferases, and sulfotransferases into more polar form to be excreted through bile and urine. 7 The essay explains polymorphism in light of CYPs.
CYP450s are responsible for more than 80% of all phase-I metabolism of clinically used drugs 12 as well as many chemicals. Many adverse drug reactions and therapeutic failure are the consequences of the polymorphic forms of CYP450s. 13 Polymorphic CYP450s (in particular, CYP2C9, CYP2C19 and CYP2D6) are responsible for approximately 40% of CYP450-mediated drug metabolism, making drug dosing problematic and in general, 4 phenotypes are identified namely poor metabolizers (PMs), intermediate metabolizers, extensive metabolizers (EMs), and ultrarapid metabolizers (UMs). 13 
CYP2C9
CYP2C9 is known to be involved with metabolism of up to 15% of all drug undergoing Phase-I metabolism. 14 CYP2C9 can undergo significant polymorphism (up to 40% Caucasian populations are carriers of partially defective gene for CYP2C9) and is prominently involved in metabolism of drug with narrow therapeutic window such as phenytoin, (s)-warfarin and tolbutamide. 14, 15 The most common variant alleles Caucasians bear are CYP2C9*2 (Arg144Cys) and CYP2C9*3 (Ile359Leu) which occur significantly very less in African, Americans and Asian. 6 Explanation of Figure 1 16 Warfarin, mainly exists as R-warfarin and S-warfarin, those are differentially metabolised. S-warfarin is about three times as potent as R-warfarin when administered as a racemate. Two known allelic variants of cytochrome P450 CYP2C9 (the primary enzyme that catalyses the conversion of S-warfarin to inactive metabolites) are CYP2C9*2 and CYP2C9*3, those differ from the wild type CYP2C9*1 by a single amino acid substitution in each January/July 2010 event. In case of CYP2C9*2, cysteine substitutes for arginine at aminoacid 144, while in CYP2C9*3, leucine substitutes for isoleucine at residue 359 of the wild type allele. 15 This point mutation inturn results in 88% and 95% less efficient than the wild-type enzyme activity respectively.
Studies on CYP2C9 and (s)-warfarin have shown 30% to 60% (CYP2C9*2) and greater than 90% (CYP2C9*3) reduction in (S)-warfarin 7-hydroxylation leading to increased risk of bleeding. 17 Another study conducted by Aithal et al 15 demonstrated that individual requiring a low warfarin dose is six times more likely to be positive for one or more of the variant alleles (CYP2C9*2 and CYP2C9*3) compared with the general population and require a very low dose of drug. Thus impaired metabolism of a narrow therapeutic index drug like warfarin can affect patients' treatment outcome; that includes delayed discharges from the hospitals due to difficulty in induction, multiple visits to the clinics, and additional unnecessary investigations with a view to seeking warfarin sensitivity.
Another most commonly prescribed drug worldwide NSAIDs, along with the increased occurrence of inflammatory diseases (such as arthritis, osteoarthritis and other inflammatory-related condition) in elderly population, exclaims an intensives to consider CYP2C9 polymorphism in treatment strategies due to the imposed additional toxicity like as warfarin. 18 An adverse effect of phenytoin has also been reported in a Japanese patients due to CYP2C9*4 allele. 6, 14 The knowledge of CYP2C9 genotype can promote therapeutic efficacy by risk identification of the patients when deciding on treatment with warfarin and they can be maintained with low dose warfarin or alternative drug therapy.
CYP2C19
The short-and long-term management of acidrelated intestinal disease largely depends on proton pump inhibitors (e.g. omeprazole/esomeprazole, lansoprazole, pantoprazole, rabeprazole. Their elimination mainly occurs through the hepatic route and the polymorphic CYP2C19 is involved in their metabolism.
On the basis of genetic association with this enzyme activity, polymorphism of this enzyme is classified as rapid extensive metaboliser (REM), where mutation does not occur at alleles and enzyme generated from both the non-mutant alleles; IMs (intermediate metaboliser), where mutation occurs at one allele but other allele is normal and normal enzyme can be originitated from this allele; PMs (poor metaboliser), where both of the alleles have mutations and production of enzyme is not possible, thereby individual lacks of enzyme activity. 20 It has also been reported that there are inter-ethnic variations are also present in the frequencies of PMs of CYP2C19; that is 2.5% in white Americans, 2% in African Americans, 3.5% in White Europeans, 4.8% in shona Zimbabweans, 19.8% in the Chinese-Han population, 13.4% in ChineseBai population, 12.6% in Korean and 18-22.5% in the Japanese populations. 15 Consequently, these people will respond differently to a specific recommended dose of drug and drug metabolism will also differ from normal people. Treatment with anti-ulcer agents to reach a expected plasma level depends on the CYP2C19 phenotype; it has been studied that treatment with low dose omeprazole (20 mg) in peptic ulcers, the cure rates were very low in EMs (25%), higher in IMs (50%) and complete in PMs (100%) and long term treatment with omeprazole can be adjusted according to the CYP2C19 phenotype, [21] [22] [23] furthermore, metabolic pathways also differ in PMs rather than other 2 groups; in PMs sulfoxidation is the main pathways for omeprazole metabolism and in EMs and IMs, that is hydroxylation. 20 Thus, treatment with PPI for acid inhibition can vary at different CYP2C19 genotype groups because the healing rate in peptic ulcer (PU, target pH > or = 3) and gastroesophageal reflux disease (GERD, target pH > or = 4) and the eradication of Helicobacter pylori (Hp) depend on a long-lasting (> or = 16 hours) and effective inhibition of acid secretion. Study with lansoprazole (+ amoxicillin, clarithromycin, metronidazole) the eradication rates were 100, 98 and 80% in PM, IM and EM, respectively, and in patients with GERD treated with lansoprazole (30 mg/ day) the healing rates after 8 weeks were much higher in PM (85 -100%) and IM (68 -95%) than in EM (46 -77%). 24 Studies on different ethnic population for CYP2C19 polymorphism demonstrated that CYP2C19 activity is absent in PMs, common among Asians (10-25%) than Caucasians (1-3%) or African-Americans (4%). 23 Thus, a genotype-adjusted dosage regimen will improve therapeutic efficacy of PPIs.
Explanation of figure same as explanation of Figure 1
The dosage of Nortriptyline can vary from 30mg to 50 mg in PMs to 500mg in UMs depending upon the CYP2D6 phenotype. 25 Codeine is ineffective in CYP2D6 PMs due to inability to convert into active morphine by CYP2D6 while in CYP2D6 UMs adverse effects can occur due to formation of high level of active morphine. 26 
CYP2D6
CYP2D6 metabolises wide range of drugs such as antidepressants, antipsychotics, antiarrhythmics, â-blockers, analgesics, and many others. The CYP2D6*4 allele occurs in higher frequency in Caucasians (22%) (Incidence of PMs is 5% to 10%), 3.5% to 8% in African Americans, and around 1% in Asian populations whereas CYP2D6*10 allele occurring at higher frequency in Asians (50%) 6 and CYP2D6*17 allele at higher frequency in Africans, 6 are responsible for decreased catalytic activity. 
Pharmacogenetic polymorphism in drug transporters
Transporters have become the major focus these days due to the increasing evidences that they are vital in drug absorption, disposition, toxicity and efficacy that is pharmacokinetic (PK) and pharmacodynamic (PD) profiles. [9] [10] [11] Moreover, transporter-mediated drug interactions have been augmented by many experiments so some extent. For example the nephrotoxic uptake of cidofovir through kidney epithelial human organic anion transporter (hOAT) has been reduced by Probenecid by inhibiting hOAT transporter. 10 Alteration in PK and PD profiles can alter therapeutic profile of drug. Studies have shown that polymorphism of drug transporters are associated with alteration in PK-PD profile of clinically useful drugs. 27 Some known substrates for transporters and their inhibitors are depicted in the table below to give a general outline of drug effect on transporter. The impact of polymorphism in drug transporter is discussed as it follows.
This article is focusing on the impact of polymorphism in three principal transporters ABC (ATPbinding cassette), OAT (organic anion transporter), OCT (organic cation transporter) and its consequence on therapeutic efficacy of drug as studies also has been carried more in these transporters. The representative figure of the principal transporters with the substitution with altered nucleotide leading to polymorphism of the transporters has been shown in figure 1, 2(a) and 2(b) where abbreviation suggests as BCRP: Breast cancerresistance protein; Exc: Extracellular; Inc: Intracellular; Mnb: Membrane; MRP: Multi-drug resistance-associated protein; NBD: Nucleotide-binding domain; P-gp: Pglycoprotein. 
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Polymorphisms of transporters in different ethnic populations
Ethnic variation in the frequency of drug transporters can be a promising factor for justifying pharmacotherapy. The table below is meant to show the ethnical variation in the transporter genes which can possibly be an evidence for the pharmacogenetic polymorphism altering therapeutic efficacy. As mentioned in the genetic variation in metabolic enzymes above that different races show phenotypic and genotypic variation and the resultant altered therapeutic profile, the table below is to subside the same notion of therapeutic variation. For an example, It has been reported that there are inter-ethnic variations are present in the frequencies of PMs of CYP2C19; that is 2.5% in white Americans, 2% in African Americans, 3.5% in White Europeans, 4.8% in shona Zimbabweans, 19.8% in the Chinese-Han population, 13.4% in ChineseBai population, 12.6% in Korean and 18-22.5% in the Japanese populations. 20 So, this people will respond differently to a specific recommended dose of drug and drug metabolism will also differ from normal people.
Impact of transporter polymorphism on pharmacotherapy
Pharmacokinetic and Pharmacodynamic consequences:
The genetic polymorphism of transporters have shown to alter the pharmacokinetic parameters such as area under the curve (AUC) and maximum plasma concentration (Cmax) those are the major determinants of pharmacotherapy. Thus, changes in AUC and Cmax can lead to potential therapeutic failure or toxicity in narrow therapeutic index drugs such as phenytoin, digoxin. 5 Studies also suggests that pharmacogenetic polymorphism is also associated with pharmacodynamic consequence of ABCB1 gene polymorphism for HIV drugs, antiepileptics, chemotherapy, P-gp substrates (immunosuppresants and tricyclic antidepressants), and others. Most of them are associated with response other than needed.
Pharmacogenetic polymorphism in drug targets
Most drugs show their effect through drug targets such as receptors, ion channels including enzymes and many of the drug targets bear polymorphism leading to altered therapeutic response. 8 Genetic polymorphism of drug targets can be an important and interesting function for therapeutic efficacy.
Studies done on â 2 -adrenoreceptor (coded by ADRB2 gene) illustrates link between genetic polymorphisms in drug targets and clinical responses. 28 Single-nucleotide polymorphism in ADRB2 resulted in altered signal transduction. Studies 28 done on agonist-mediated vasodilation and desensitization with isoproterenol in one genotype (homozygous for Arg at ADRB2 codon 16) showed nearly complete densitization and significant reduction in venodilation whereas in another genotype (homozygous for Gly at ADBR2 codon 16) no significant change in venodilation was seen. Studies on genetic polymorphism and long term regular inhalation therapy of â-agonist showed different influence of those drugs in genotype-showing risk (deleterious or nonbeneficial effects) to codon 16 Arg/Arg genotype in terms of therapy, suggesting alternative therapy or earlier initiation of antiinflammatory agents, or both. 28 Study conducted by Evans & Johnson 29 on clonazipine response and polymorphism (including aadrenergic receptors, dopamine receptors, serotonin receptors, histamine receptors and serotonin transporters) in schizophrenic patients showed significant predictive values (76% positive, 81% negative) and sensitivity (96%) in identification of the patients with improvement with clonazipine and 38% specificity in identification of the patients with minimal response to the drug.
Pharmacogenetic based diagnostics (PGDx) in therapeutic decision making
The consequences of polymorphism in drugmetabolizing enzyme, drug transporters and drug targets were explained above. Most of the consequences were a mixed bag of ineffectiveness and toxicity. As simple as to understand the drug is not within the therapeutic index. PGx has brought up the reasons of failure of therapy and it is the PGx itself that can help in success of therapy. All is needed is to put some brains to make it work. A key factor in PGDx in therapeutic decision making that can assist, in part, is the appropriate dose adjustment of drug, where genetic polymorphism can lead to major changes in pharmacokinetic parameters. 5 Kirchheiner et al 5 have illustrated the role of dose adjustment in therapeutic decision making with theoretical drug example that is supposed to be a substrate of genetically polymorphic enzyme CYP2D6. The theoretical standard dose was taken with relevant assumptions and the illustration has been depicted in the graph below. The AUC in different alleles (UMs=Ultra Metabolizers, EMs=Extensive Metaboilizers, IMs=Intermediate Metabolizers and PMs=Poor Metabolizers) were compared with each other and also with standard. AUC for UMs, EMs, IMs and PMs were 50, 100, 150 and 200 units giving a linear relationship between number of active alleles of a drug metabolism gene and extent of drug clearance, typical to many antidepressants. 5 According to the AUC values the PMs should receive one quarter of dose that is administered to UMs. Dose adjustment is therefore essential to produce good therapeutic efficacy, equalizing AUC and Cmax would be the main aim (principle of bioequivalence). Dose adjustment according to genotype can help in achieving uniform drug exposure which can indeed prevent drug toxicity as well as therapeutic failure in cases like depression, cancer. 5 However, genotypic data on many drugs are not available which could help in more precise decision making by dose adjustment. 5 [30] [31] [32] [33] 5 The dose adjustments in the graph are based on differences in dose-related pharmacokinetic parameters (clearance, AUC, steady state concentration) caused by particular genotypes. 5 
CONCLUSION
Pharmacogenetic polymorphism can be a useful marker for understanding the variation in pharmacokinetics and pharmacodynamics of drugs that have narrow therapeutic index as well as are clinically useful. The approach can be applied in the early stage of drug development as well as in clinical praxis. The nascent approaches to pharmacotherapy from the perspective of pharmacogenetic polymorphism seem lot more promising. However, there are still many loop holes to be buried before revolutionising the treatment protocol persisting since long time. There is a need to develop concrete methodology for in-vitro to in-vivo correlation. The pros of the newer approaches still need more justification and there may be more cons still waiting. The success of pharmacogenetics can be charismatic for risk assessment of an individual against a particular drug. It seems there will be no therapeutic failure of drug as far as correct way is followed because the concept of pharmacogenetics based on polymorphism is systematic, scientific and more importantly evidence based. But discovery for goodness has not always proved good for mankind. Strict guiding laws, rules and regulation are critically important. There is always a fear for unpredicted misuse. Biomedical databases need to be very confidential. There is also a necessity of professional experts to handle pharmacogenetic approaches not only in theories but also in practice.
